مقایسه کارایی بالینی واکسن جدید آنفلوانزای پرندگان با یک واکسن تجاری
/علی ترابیان
: دامپزشکی
، ۱۳۹۶
، راشدی
چاپی
کارشناسی ارشد
دامپزشکی
۱۳۹۶/۱۱/۱۷
تبریز
بیماری آنفلوانزای پرندگان، بیماری عفونی بسیار واگیردار است، که اهمیت اقتصادی و بهداشت عمومی دارد و در پرندگان، انسان و سایر پستانداران رخ میدهد .تحت تیپ H۹N۲ ویروس عامل بیماری آنفلوانزای پرندگان در ایران بومی است، لذا برای کنترل آن از سیاست واکسیناسیون استفاده میشود .واکسنهای تجاری موجود دارای روغن معدنی بعنوان ادجوانت هستند که در جوجه های گوشتی از بدن حذف نمی شوند .ترکیبات آلومینیوم بعنوان ادجوانت ترکیباتی بی خطر هستند لذا در این تحقیق با استفاده از ترکیب آلومینیوم پتاسیم سولفات، دو نوع واکسن غیرفعال آنفلوانزای پرندگان با فرمول متفاوت تهیه و ایمنی زایی آنها با دوتا از واکسنهای تجاری موجود در بازار ایران مقایسه گردید .برای این منظور ۱۸۰ قطعه جوجه یکروزه گوشتی تجاری تهیه و به شش گروه تقسیم شدند .در ۱۴ روزگی به گروه اولPBS ، به گروه دوم واکسن مورد مطالعه اول، به گروه سوم واکسن مورد مطالعه دوم تزریق شد، گروه چهارم هیچ واکسنی دریافت نکردند، گروه پنجم واکسن تجاری اول و گروه ششم واکسن تجاری دوم تزریق شد .میزان مصرفی غذایی ، وزن جوجهها و تیتر آنتی بادی علیه تحت تیپ H۹N۲ از روز ۱۴ تا ۴۹ بهصورت هفتگی اندازه گرفته شد .دادهها به روش آنالیز واریانس یکطرفه و روش تکمیلی دانکن بررسی گردید
Avian Influenza is a highly contagious infectious disease that has an economic and public health significance and occurs in birds, humans and other mammals. Avian influenza virus subtype H9N2 is enzootic in Iran then, vaccination policy is used for control of it. Available commercial vaccines contain mineral oil as adjuvant that is not removed from the body of the broiler chickens. Aluminum compounds as vaccine adjuvants are safe, therefore, in this study aluminum potassium sulfate was used as an adjuvant for preparation of two inactivated avian influenza vaccines with different formula, and then, the immunogenicity of them compared with immunogenicity of two available commercial vaccines in Iran. For this reason, 180 one-day-old commercial broiler chicks were divided to six groups. At14 days of age the first group received PBS, second group received the first new vaccine, the third group received the second new vaccine, the fourth group did not received anything, the fifth group received the first commercial vaccine, and sixth group received the second commercial vaccines. Feed intake, weight gain, and titers of antibodies to subtype H9N2 were parameters that weekly recorded from 14-49 days of age. Data were analyzed by one-way ANOVA and Duncan multiple range tests by using of SPSS software version 22. The mean feed intake in first, second, and third week of post vaccination was significantly different between group six and other groups (P<0.05). The mean weight gain was not significant between groups (P>0.05). The mean HI titers were significant in the third week after vaccination between the sixth group and the other groups; in fourth week post vaccination there was significant difference between group six and five, between group five and other groups and also between group six and other groups; in fifth week post vaccination there was significant difference between the six and five groups with the other groups (P<0.05). The results showed that the prepared vaccines unable to induce antibodies against avian influenza subtype H9N2, although they do not negative effect on production parameters. The lack of absorption of the antigens of the virus by the adjuvant was the main reason. About two commercial vaccines, the results indicated that they both induce the highest HI titers after five weeks of vaccination, but the titers cannot induce protective immunity. It is also cleared that there is no interfere between maternal immunity and acquired immunity